PMID- 24894839
OWN - NLM
STAT- MEDLINE
DCOM- 20150616
LR  - 20211021
IS  - 1699-3055 (Electronic)
IS  - 1699-048X (Linking)
VI  - 16
IP  - 11
DP  - 2014 Nov
TI  - Analysis of survival factors in patients with intermediate-advanced 
      hepatocellular carcinoma treated with transcatheter arterial chemoembolization 
      combined with sorafenib.
PG  - 1012-7
LID - 10.1007/s12094-014-1189-3 [doi]
AB  - PURPOSE: To retrospectively analyze the efficacy and safety of transcatheter 
      arterial chemoembolization (TACE) in combination with sorafenib for the treatment 
      of patients with intermediate-advanced hepatocellular carcinoma (HCC) and assess 
      the prognostic impact of baseline characteristics. METHODS: Patients with 
      intermediate-advanced HCC received TACE combined with sorafenib in this Phase 2 
      clinical trial. The primary outcome was median time to disease progression 
      (mTTP). Secondary outcomes were median overall survival (mOS), the disease 
      benefit rate and the sorafenib-related adverse events (AEs). Baseline 
      characteristics' impacts on prognosis were analyzed by univariate COX 
      proportional hazards regression model. RESULTS: From June 2008 to June 2013, 75 
      patients were enrolled. At the end of the study, 54 patients were dead or lost to 
      follow-up and 21 patients survived. This combination therapy resulted in a mTTP 
      of 7.09 months (95 % CI, 1.5-45 months) and a mOS of 11.44 months (95 % CI, 
      1.5-45 months). The disease benefit rate was 88 %. Child-Pugh score (P = 0.000), 
      Eastern Cooperative Oncology Group performance status (P = 0.001), Barcelona 
      Clinic Liver Cancer stage (P = 0.000), sorafenib treatment regimen (P = 0.001), 
      presence of extrahepatic metastasis (P = 0.002), and type of tumor (P = 0.027) 
      were significantly correlated with OS. Multivariate analysis revealed Child-Pugh 
      score (P = 0.001) and BCLC stage (P = 0.002) as significant independent 
      prognostic predictors for OS. AEs were HFSR (18.7 %), gastrointestinal reactions 
      (13.3 %), liver dysfunction (6.7 %), myelosuppression (5.3 %), fatigue (4 %), and 
      hypertension (1.3 %). CONCLUSIONS: TACE in combination with sorafenib might have 
      acceptable safety and efficiency in the treatment of intermediate-advanced HCC.
FAU - Zheng, J
AU  - Zheng J
AD  - Department of Interventional Radiology, Zhejiang Cancer Hospital, No. 38 Guangji 
      Road, Banshanqiao, Hangzhou, 310022, China, zhengjp_2013@126.com.
FAU - Shao, G
AU  - Shao G
FAU - Luo, J
AU  - Luo J
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
DEP - 20140604
PL  - Italy
TA  - Clin Transl Oncol
JT  - Clinical & translational oncology : official publication of the Federation of 
      Spanish Oncology Societies and of the National Cancer Institute of Mexico
JID - 101247119
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Phenylurea Compounds)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/*administration & dosage
MH  - Carcinoma, Hepatocellular/mortality/*therapy
MH  - Chemoembolization, Therapeutic/*methods
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Liver Neoplasms/mortality/*therapy
MH  - Male
MH  - Middle Aged
MH  - Niacinamide/administration & dosage/*analogs & derivatives
MH  - Phenylurea Compounds/*administration & dosage
MH  - Proportional Hazards Models
MH  - Sorafenib
EDAT- 2014/06/05 06:00
MHDA- 2015/06/17 06:00
CRDT- 2014/06/05 06:00
PHST- 2014/03/25 00:00 [received]
PHST- 2014/05/17 00:00 [accepted]
PHST- 2014/06/05 06:00 [entrez]
PHST- 2014/06/05 06:00 [pubmed]
PHST- 2015/06/17 06:00 [medline]
AID - 10.1007/s12094-014-1189-3 [doi]
PST - ppublish
SO  - Clin Transl Oncol. 2014 Nov;16(11):1012-7. doi: 10.1007/s12094-014-1189-3. Epub 
      2014 Jun 4.